Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was formed to produce improved, more potent shots that are simpler to manufacture.

I have been a technology journalist for 30-plus years and have covered just about every kind of computer gear—from the 386SX to 64-core processors—in my long tenure as an editor, a writer, and an ...